Piper Sandler Merchant Banking logo

Piper Sandler Merchant Banking

Crunchbase
Pitchbook
Crunchbase

Deals on record

5

Common Fundraising Type

Series C

Saluda Medical logo
Saluda Medical

Medical device

Wellington Management logo
TPG Life Sciences Innovation logo
T. Rowe Price Associates logo
Redmile Group logo
Piper Heartland Healthcare Capital logo
Fidelity Management & Research Company logo
Action Potential Venture Capital logo

Saluda Medical develops and commercializes the Evoke® System, a closed-loop spinal cord stimulation device for managing chronic pain.

Equity
$100M
01/10/2025
Article

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

Series D
$181.4M
11/12/2024
Article
AvenCell logo
AvenCell

Cell therapy

Novo Holdings logo
F-Prime Capital logo
NYBC Ventures logo
Piper Heartland Healthcare Capital logo
Eight Roads Ventures Japan logo
Blackstone Life Sciences logo

AvenCell Therapeutics, Inc. develops a Universal Switchable CAR-T cell therapy platform for treating hematologic malignancies and autoimmune diseases.

Series B
$112M
10/22/2024
Article
Graylog logo
Graylog

Digital Security

Silver Lake Waterman logo
Piper Sandler Merchant Banking logo
Harbert Growth Partners logo

Graylog develops tools for detecting, analyzing, and responding to digital security threats, with a focus on collecting, storing, and analyzing log data for IT troubleshooting and error detection, and has recently expanded into cybersecurity with products for API threat monitoring, security analytics, incident investigation, and anomaly detection.

Hybrid C
$39M
10/31/2023
Article
Avalyn Pharma logo
Avalyn Pharma

Biopharmaceutical

Perceptive Xontogeny Venture Funds logo
Wellington Management logo
Vida Ventures logo
T. Rowe Price Associates logo
SR One logo
Rock Springs Capital logo
RiverVest Venture Partners logo
Pivotal bioVenture Partners logo

Avalyn Pharma is a biopharmaceutical company that develops inhalation therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases, with a focus on creating new inhaled formulations of approved medicines.

Series C
$175M
09/27/2023
Article